Law360, New York (January 19, 2018, 1:58 PM EST) — The Federal Circuit has given Teva Pharmaceuticals until Monday to reply to Helsinn Healthcare’s last-ditch bid to keep Teva from launching a generic version of Helsinn’s Aloxi anti-nausea drug while it seeks to take its patent case to the U.S. …
